Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space of oral obesity therapies. | Eli Lilly has returned to Nimbus Therapeutics ...

Recent advances in nanomedicine have brought significant improvements to drug delivery systems, yet persistent hurdles remain ...

Seattle biotech startup Rhizome Research has emerged from stealth with technology for creating small-molecule drug candidates ...

Experts have been raising concerns about “AI washing.” One of these experts, futurist Bernard Marr, has said that AI washing “involves exaggerating the capabilities of a product or service that is ...

The artificial intelligence-powered drug designer Atomwise has raised $123 million in venture capital funding, to both scale up its platform and its partnerships with large biopharma companies, and to ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

SCIENTIFIC PAPERS are normally models of discreet understatement. They are also (or are at least supposed to be) loaded with the information needed for others to replicate their findings. Not this one ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...